A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.

Related Articles

A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.

Mol Med Rep. 2015 Sep;12(3):4370-5

Authors: Xu CW, Cai XY, Shao Y, Li Y, Shi MW, Zhang LY, Wang L, Zhang YP, Wang LP, Tian YW

Abstract
The echinoderm microtubule associated protein like 4‑anaplastic lymphoma kinase (EML4‑ALK) fusion is almost mutually exclusive to epidermal growth factor receptor (EGFR) or K‑RAS mutation in non‑small cell lung cancer (NSCLC), and it is extremely rare for patients to exhibit both mutations. The present study reported the case of a 71-year‑old female diagnosed with adenocarcinoma, exhibiting mutations in EGFR and EML4‑ALK. The present study treated this patient with EGFR‑TK inhibitors, as the first line therapy, and gefitinib therapy revealed a good response until now. In addition, previously reported cases and associated literature were reviewed. The present study provided a greater understanding of the molecular biology and optimal treatment for patients with NSCLC with >1 driver mutation.

PMID: 26130140 [PubMed - indexed for MEDLINE]

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1CMrD0A
via IFTTT